RA Capital Management, LP

RA Capital Management (10% owner) purchases 67,669 shares at avg $24.97 across 2 transactions, holding 6,444,637 shares post-transaction

RA Capital Management executed two separate purchases totaling 67,669 shares for $1,689,818.48 on 2026-06-15 and 2026-06-16, increasing its position by 1.1% to 6,444,637 shares. This builds on a consistent pattern: all 5 prior purchases at COAG were well-timed at the 90-day mark, with positive cumulative returns of +2.2% to +4.4%. The stock currently trades at $26.45, above the blended transaction price of $24.97 but -27.8% from its 52-week high of $36.61, and the company is operating at a net loss of $-22,687,000.00 with a market cap of $1,235,358,094.50. The consistent accumulation alongside a 100% track record at this specific ticker suggests methodical conviction, though the macro position (negative earnings, significant distance from highs) warrants close attention to whether the insider's prior success at COAG continues.

Director RA Capital Management buys 531,326 shares at $8.66 avg over 3 days despite stock down 8.9% in 30 days; stock still -38.7% from 52-week high.

RA Capital Management filed a Form 4 disclosing 3 separate purchases totaling 531,326 shares for $4,599,903.46 across a three-day window (June 12–16, 2026), with a blended average price of $8.66. The transactions increased the director's holding to 16,763,043 shares from 16,231,717 shares. Notably, this purchase occurred as the stock was trading -38.7% from its 52-week high of $14.53 and down 8.9% over the prior 30 days, though it has rebounded 53.6% over 90 days. The company is unprofitable with a quarterly revenue of $251,000 and full-year net income of -$23,516,000; annual revenue growth is -100.0%, indicating a material revenue decline. The director's prior purchase at ARTV (May 11, 2026) delivered a 90-day return of -30.6%, suggesting this ticker has not aligned with the director's cross-ticker buy success rate (93.33% 90-day win rate across all open-market holdings). The accumulation during a price decline and amid negative fundamentals warrants attention to whether this represents a conviction signal or portfolio mechanics.

RA Capital Management director acquired 21,188,750 shares ($423.8M) at $20.00 in PIPE placement at PBLS IPO.

RA Capital Management, LP, acting as director of Parabilis Medicines, completed 2 separate share purchases totaling 21,188,750 shares (21.19M shares) for $423,775,000.00 ($423.8M) at $20.00 per share on June 11, 2026. This transaction is a private placement (PIPE) allocation tied to PBLS's recent IPO, not a discretionary open-market purchase, so it reflects allocation participation rather than a conviction-driven buying signal. The company is trading at $25.01 as of June 15, 2026—four trading days after listing—representing modest outperformance versus the $20.00 subscription price. RA Capital's post-transaction non-derivative holdings of 2,648,278 shares reflect only a portion of the investor's total position; earlier preferred stock holdings are no longer reflected post-transaction, indicating conversion or redemption as part of the IPO transition.

RA Capital Management accumulates 1,027,722 shares in 3 purchases (June 9-11) at $7.44 average; stock down -24.7% in 30 days vs. -44.9% from 52-week high.

RA Capital Management, LP filed Form 4 disclosing 3 separate purchases totaling 1,027,722 shares for $7,650,148.29 at a blended average price of $7.44. The insider now holds 16,231,717 shares post-transaction, a +6.8% increase. At current price of $8.00, the stock is -24.7% over 30 days and -44.9% from its 52-week high of $14.53. The company reported latest quarterly revenue of $251,000.00, annual revenue growth of -100.0%, and net income of $-23,516,000.00, indicating a deeply unprofitable position with materially contracted revenue. This accumulation occurs while ARTV trades near mid-range of its 52-week spread and after the insider's prior buy on 2026-05-11 experienced a -35.6% loss over 30 days. The cross-ticker track record shows 93.33% accuracy on prior buys with +5.9% average 30-day returns, but the same-ticker history is unfavorable: 0 of 1 prior buys at ARTV were well-timed at the 90-day mark.

RA Capital Management (10% owner) purchased 4,798 shares at $24.96 avg across 2 transactions, bringing holdings to 6,376,968 shares

RA Capital Management executed 2 separate purchases totaling 4,798 shares for $119,776.18 on May 19–20, 2026, at an average price of $24.96. The transaction increased its stake from 6,372,170 shares to 6,376,968 shares, representing a net change of purchased 4,798 shares. Given Hemab's recent listing (14 trading days), the current price of $26.30 reflects early-stage market discovery. The modest incremental purchase and the minimal percentage increase in holdings suggest a measured approach rather than a concentrated accumulation event.

RA Capital Management bought 6,387 shares of COAG at $24.90, adding $159,036.30 to a 6.37M-share position in a recently listed stock.

RA Capital Management, LP, a 10% owner of Hemab Therapeutics Holdings, Inc. (COAG), purchased 6,387 shares at $24.90, bringing its total holding to 6,372,170 shares. The stock is in its early trading life with only 9 trading days since listing, and the current price of $28.37 sits above the transaction price, suggesting the position is in the money relative to this purchase. While the incremental dollar value of $159,036.30 is modest relative to the firm's existing 6.37M-share stake, the continued accumulation by a major 10% owner shortly after listing is a notable signal of sustained institutional commitment. Investors should monitor whether RA Capital continues to add to its position as the company establishes its post-listing trading history.

Ra Capital Management increases stake in ARTV by 75% with ~$75M open-market purchase; first buy at this company in 36 months.

Ra Capital Management, a board director and major shareholder, deployed approximately $75 million to acquire a substantial block of Artiva shares, expanding its indirect stake by more than 75 percent—the largest single acquisition in the fund's 36-month filing history at this company. The purchase occurred while the stock trades well below its 52-week high and follows a dramatic rally over the prior quarter, yet the company remains unprofitable with revenues declining sharply and significant annual net losses. Notably, this represents Ra Capital's first open-market purchase of ARTV shares on record, despite the fund's extensive trading activity across other holdings over the past three years—suggesting a deliberate shift toward this particular investment after a period of inactivity. The timing and scale of the buy are notable given the stock's weak fundamentals, though Ra Capital's prior open-market purchases across its broader portfolio have demonstrated a strong track record of capturing upside gains within 90 days.

Ra Capital Management (10% owner) acquired 51,258 shares across five open-market purchases at newly public COAG, its 79th open-market purchase in 36 months.

Ra Capital Management, a substantial institutional holder, spent approximately $1.27 million to acquire over 51,000 shares of Hemab Therapeutics across five trades, each priced just above or below the newly-public stock's listing reference point. While the stock has traded below its 52-week high since IPO, this represents typical portfolio activity for a fund rather than insider conviction—Ra Capital's extensive filing history shows 79 open-market purchases over the past three years alongside 92 open-market sales, reflecting active portfolio management rather than directional betting on the company. The purchases do occur at a point where the stock has pulled back from its post-IPO highs, aligning with the historical pattern that when Ra Capital has been a net buyer in prior transactions, subsequent returns have been positive over longer horizons. However, this is institutional rebalancing activity, not a signal of executive or board-level confidence in COAG's prospects.

Ra Capital Management, 10% owner and director, deployed substantial capital across multiple open-market purchases at Hemab Therapeutics (COAG).

L.P. Ra Capital Management, a director and significant institutional shareholder, executed a series of open-market purchases totaling approximately $52.2 million across three trading days, adding nearly 2.9 million shares to its position. The timing coincides with the stock trading at its lowest point in its brief public history, suggesting the fund saw a tactical opportunity despite the steep discount from recent highs. Ra Capital's track record shows a strong history with prior purchases — all completed within the past 90 days have been profitable, indicating disciplined entry timing. This purchase represents a substantial reaffirmation of confidence in Hemab's prospects: Ra Capital is not a passive holder but an active accumulator willing to deploy significant capital when valuations compress. The scale and conviction of this institutional accumulation warrant monitoring as a potential signal that sophisticated capital sees value below current prices.

RA Capital sold 630,374 shares (19.7% of holdings) for $10.2M at avg $16.14 vs. current $15.17; 5 consecutive VOR sales in 5 days while stock -71.6% from 52-week high.

RA Capital Management executed 2 separate sales totaling 630,374 shares for $10,174,787.59, reducing holdings from 3,197,619 shares to 2,567,245 shares—a reduction of 19.7% of pre-transaction holdings. The sales occurred at $16.28 and $15.77 on April 17 and April 20, blending to $16.14 per share, slightly above the current price of $15.17. Most significantly, this filing reflects the third and fourth transactions in a 5-day pattern: RA Capital sold on April 9, 10, 13, 14, and 15—before filing this Form 4 on April 17 for the April 17 and April 20 sales. This high-frequency exit pattern occurs while the stock trades 71.6% below its 52-week high of $53.40 and while the company reported a full fiscal year net loss of $812,684,000 against a market cap of $741,016,635.68. The concentration of sales within days of each other, without measurable outcomes yet from the prior 5 trades at this ticker, suggests sustained pressure to liquidate a significant director-level stake during a period of pronounced valuation compression.